



News release

Antiparasiticide with the broadest spectrum of action:

Danish study confirms efficacy of Advocate® against lungworms in dogs

Leverkusen, October 31, 2007 – Use of the antiparasiticide Advocate® to combat lungworms (*Angiostrongylus vasorum*) in dogs is safe and effective, according to a recent study conducted by the University of Copenhagen. Over a two-year period, scientists from the Department of Small Animal Clinical Sciences, Faculty of Life Sciences, investigated the effect of Advocate® on dogs that had become naturally infected with this parasite. More than 85 percent of the four-legged patients had recovered just 42 days after the first treatment.

The Danish team of scientists headed by Jakob L. Willesen stressed the need for effective drug products in the battle to stem the growing spread of lungworm as well as a greater understanding of the disease and the reason behind its apparent spread into new geographic areas. The parasite, which is transmitted by various species of snail, inhabits the blood vessels in the lungs, thereby causing a severe lung disease. According to the scientists, lungworms are already a problem in Denmark, the United Kingdom, Ireland, southern France, northern Spain and Brazil. It is also likely to spread further.

In August 2007, the European Medicines Agency (EMA) extended the indications of Advocate® for dogs to cover *Angiostrongylus vasorum* (lungworm) and *Trichodectes canis* (mallophagean louse), thus confirming the efficacy of the established antiparasiticide against these two pathogens. Advocate®, which is marketed under the name Advantage Multi® in some countries, has a broader spectrum of action against ectoparasites and endoparasites than any other parasiticide approved for dogs.

The proven and reliable action of this product featuring a unique combination of the active ingredients imidacloprid and moxidectin can be used to control fleas, ear mites, mange mites, *Demodex* mites, mallophagean lice, heartworms, lungworms and gastrointestinal nematodes (ascarids, hookworms and whipworms) in various stages of development.

As a spot-on product, Advocate® complies with the most up-to-date pharmacological standards and has proved to be particularly successful in practical applications. For example, Advocate® is the only spot-on product that is effective against the three main types of mites that infest dogs.

In addition to Advocate® for dogs, which is available in four pack sizes (for dogs with a body weight of up to 4 kg, from 4 to 10 kg, from 10 to 25 kg and up to 40 kg), Advocate® is also available for cats in the following pack sizes: for cats with a body weight of up to 4 kg and cats weighing between 4 and 8 kg.

Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading innovative companies in the health care and medical products industry. The company combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The company's pharmaceuticals business operates under the name Bayer Schering Pharma AG.

Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide.

Contact:

Dr. Hermann-Josef Baaken, Tel.: +49 214-30-53366

E-mail: hermann-josef.baaken@bayerhealthcare.com

Just a click away – our press service with images and texts online:

www.viva.vita.bayerhealthcare.com

hb/ken

Forward-Looking Statements

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the

estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.